Tracer library / [177Lu]Lu-Gemini
[177Lu]Lu-Gemini
Also written as [Lu-177]Lu-Gemini
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- Bivalent DOTA-based radiohapten (DOTA-Bn-thiourea-PEG4-thiourea-Bn-DOTA)
- Target / mechanism
- Anti-DOTA bispecific antibody (anti-GPA33/anti-DOTA IgG-scFv BsAb) pretargeting for DOTA-PRIT, binding GPA33 tumor antigen indirectly via BsAb PMID 39168519
- Clinical application
- Pretargeted radioimmunotherapy (PRIT) of GPA33-expressing colorectal carcinoma, including liver metastases, in preclinical mouse models PMID 39168519
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | >98% | Gemini ([177Lu]Lu-ABD-PEG4-Lu-ABD) | 40521192 2025 Theranostics Monovalent [177Lu]Lu-ABD and bivalent [177Lu]Lu-Gemini were prepared as described previously 18, 19, 26, 27. - average radiochemical conversions > 99% |
| — | — | — | — | >99% | Gemini | 39168519 2024 J Nucl Med |
Need this precursor?We can point you to suppliers for [177Lu]Lu-Gemini, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39168519: 'Gemini (DOTA-Bn-thiourea-PEG4-thiourea-Bn-DOTA, aka (3,6,9,12-tetraoxatetradecane-1,14-diyl)bis(DOTA-benzyl thiourea))'.